U.S. Markets open in 17 mins
  • S&P Futures

    3,821.75
    -24.25 (-0.63%)
     
  • Dow Futures

    30,863.00
    -219.00 (-0.70%)
     
  • Nasdaq Futures

    13,328.50
    -67.00 (-0.50%)
     
  • Russell 2000 Futures

    2,115.10
    -23.40 (-1.09%)
     
  • Crude Oil

    51.58
    -1.55 (-2.92%)
     
  • Gold

    1,842.20
    -23.70 (-1.27%)
     
  • Silver

    25.30
    -0.56 (-2.16%)
     
  • EUR/USD

    1.2164
    -0.0009 (-0.0730%)
     
  • 10-Yr Bond

    1.0910
    -0.0180 (-1.62%)
     
  • Vix

    22.94
    +1.36 (+6.30%)
     
  • GBP/USD

    1.3650
    -0.0081 (-0.5869%)
     
  • USD/JPY

    103.8710
    +0.3660 (+0.3536%)
     
  • BTC-USD

    32,430.18
    +1,946.44 (+6.39%)
     
  • CMC Crypto 200

    643.75
    +33.75 (+5.53%)
     
  • FTSE 100

    6,672.85
    -42.57 (-0.63%)
     
  • Nikkei 225

    28,631.45
    -125.41 (-0.44%)
     

What Type Of Shareholders Own The Most Number of MEI Pharma, Inc. (NASDAQ:MEIP) Shares?

Simply Wall St
·5 min read

If you want to know who really controls MEI Pharma, Inc. (NASDAQ:MEIP), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that have been privatized tend to have low insider ownership.

MEI Pharma is a smaller company with a market capitalization of US$323m, so it may still be flying under the radar of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about MEI Pharma.

View our latest analysis for MEI Pharma

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About MEI Pharma?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

As you can see, institutional investors have a fair amount of stake in MEI Pharma. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see MEI Pharma's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. It looks like hedge funds own 9.0% of MEI Pharma shares. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Our data shows that Mpm Oncology Impact Management, L.P. is the largest shareholder with 9.0% of shares outstanding. With 7.6% and 6.2% of the shares outstanding respectively, New Enterprise Associates, Inc. and BlackRock, Inc. are the second and third largest shareholders.

A closer look at our ownership figures suggests that the top 12 shareholders have a combined ownership of 52% implying that no single shareholder has a majority.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of MEI Pharma

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

I can report that insiders do own shares in MEI Pharma, Inc.. It has a market capitalization of just US$323m, and insiders have US$9.2m worth of shares, in their own names. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public holds a 27% stake in MEI Pharma. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With a stake of 7.6%, private equity firms could influence the MEI Pharma board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - MEI Pharma has 2 warning signs we think you should be aware of.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.